Safety and clinical activity of PD-L1 blockade in patients with aggressive recurrent respiratory papillomatosis
ConclusionsAvelumab demonstrated safety and clinical activity in patients with laryngeal RRP. Further study of immune checkpoint blockade for RRP, possibly with longer treatment duration or in combination with other immunotherapies aimed at activating antiviral immunity, is warranted.Trial registrationNCT, numberNCT02859454, registered August 9, 2016.
Source: Journal for Immunotherapy of Cancer - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Genital Warts | Human Papillomavirus (HPV) | Immunotherapy | Laryngeal Cancer | Papillomatosis | Respiratory Medicine | Study